Related Experiment Video
Updated: Jan 13, 2026
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Early elevation of complement-related proteins in metabolic dysfunction-associated steatotic liver disease (MASLD)
Li Shao1,2, Binbin Zhang1,3, Jing Liu3
1School of Clinical Medicine, Hangzhou Normal University, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Background:
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a quarter of the population. Although multiple studies have investigated the mechanisms underlying steatohepatitis and MASLD progression, little attention has been paid to milder cases, particularly those with normal enzyme levels. Our objective was to evaluate the molecular events in patients with MASLD and normal enzyme levels.
Methods:
We performed a proteomic analysis on serum samples from 83 healthy controls and 50 patients with MASLD. The major findings were then validated in serum samples from 35 controls and 60 patients with MASLD and normal liver enzyme levels (MASLD-NLE), as well as a male mouse model with metabolic dysfunction-associated liver steatosis and normal liver enzymes (mice-NLE) induced by a high-fat diet (HFD).
Results:
Despite having normal enzyme levels, patients with MASLD-NLE exhibited significantly higher levels of ALT, AST, γGGT, hs-CRP, uric acid and creatine compared to controls. Serum proteomics indicated elevated complement-related proteins in patients with MASLD-NLE, evidenced by elevated protein levels of C3 and CFH in both cases using different cutoffs for normal ALT levels. C3 and CFH also showed positive correlations with γGGT, hs-CRP, ALT, and uric acid levels. Additionally, the elevation of C3 and CFH was confirmed in another set of human serum samples, as well as in serum and liver samples of mice-NLE using ELISA.
Conclusions:
Our study provides novel evidence that the complement system is already activated in patients with MASLD-NLE, potentially offering new avenues for treating MASLD at an early stage.
More Related Videos
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:20Inborn Errors of Metabolism
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...